Is Cyclerion Therapeutics, Inc. (CYCN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 60.2% / 30% | 10.4% / 30% | 10.4% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 60.2% / 33% | 10.4% / 33% | 10.4% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 33.8% / 33% | 5.8% / 33% | 10.4% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 60.2% / 33% | 10.4% / 33% | 10.4% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 33.8% / 33% | 5.8% / 50% | 10.4% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 92.6% | |
| Operating Margin | -115.0% | |
| Net Margin | -77.0% | |
| Return on Equity (ROE) | -24.8% | |
| Return on Assets (ROA) | -23.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$4M |
| Free Cash Flow | -$4M |
| Current Ratio | 5.8 |
| Total Assets | $10M |
Price & Trading
| Last Close | $1.55 |
| 50-Day MA | $1.38 |
| 200-Day MA | $2.05 |
| Avg Volume | 1.6M |
| Beta | 1.0 |
|
52-Week Range
$1.03
| |
About Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cyclerion Therapeutics, Inc. (CYCN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cyclerion Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cyclerion Therapeutics, Inc.'s debt ratio?
Cyclerion Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Cyclerion Therapeutics, Inc.'s key financial metrics?
Cyclerion Therapeutics, Inc. has a market capitalization of $6M, and revenue of $2M. The company maintains a gross margin of 92.6% and a net margin of -77.0%. Return on equity stands at -24.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.